IBDEI27C ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,37350,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37350,1,3,0)
 ;;=3^Polymyalgia rheumatica
 ;;^UTILITY(U,$J,358.3,37350,1,4,0)
 ;;=4^M35.3
 ;;^UTILITY(U,$J,358.3,37350,2)
 ;;=^96292
 ;;^UTILITY(U,$J,358.3,37351,0)
 ;;=M33.20^^140^1787^204
 ;;^UTILITY(U,$J,358.3,37351,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37351,1,3,0)
 ;;=3^Polymyositis, organ involvement unspec
 ;;^UTILITY(U,$J,358.3,37351,1,4,0)
 ;;=4^M33.20
 ;;^UTILITY(U,$J,358.3,37351,2)
 ;;=^5011770
 ;;^UTILITY(U,$J,358.3,37352,0)
 ;;=M34.0^^140^1787^207
 ;;^UTILITY(U,$J,358.3,37352,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37352,1,3,0)
 ;;=3^Progressive systemic sclerosis
 ;;^UTILITY(U,$J,358.3,37352,1,4,0)
 ;;=4^M34.0
 ;;^UTILITY(U,$J,358.3,37352,2)
 ;;=^5011778
 ;;^UTILITY(U,$J,358.3,37353,0)
 ;;=E20.1^^140^1787^208
 ;;^UTILITY(U,$J,358.3,37353,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37353,1,3,0)
 ;;=3^Pseudohypoparathyroidism
 ;;^UTILITY(U,$J,358.3,37353,1,4,0)
 ;;=4^E20.1
 ;;^UTILITY(U,$J,358.3,37353,2)
 ;;=^100160
 ;;^UTILITY(U,$J,358.3,37354,0)
 ;;=L40.54^^140^1787^210
 ;;^UTILITY(U,$J,358.3,37354,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37354,1,3,0)
 ;;=3^Psoriatic juvenile arthropathy
 ;;^UTILITY(U,$J,358.3,37354,1,4,0)
 ;;=4^L40.54
 ;;^UTILITY(U,$J,358.3,37354,2)
 ;;=^5009169
 ;;^UTILITY(U,$J,358.3,37355,0)
 ;;=I73.00^^140^1787^214
 ;;^UTILITY(U,$J,358.3,37355,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37355,1,3,0)
 ;;=3^Raynaud's syndrome w/o gangrene
 ;;^UTILITY(U,$J,358.3,37355,1,4,0)
 ;;=4^I73.00
 ;;^UTILITY(U,$J,358.3,37355,2)
 ;;=^5007796
 ;;^UTILITY(U,$J,358.3,37356,0)
 ;;=N13.5^^140^1787^99
 ;;^UTILITY(U,$J,358.3,37356,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37356,1,3,0)
 ;;=3^Crosng vessel & strict of ureter w/o hydronephr
 ;;^UTILITY(U,$J,358.3,37356,1,4,0)
 ;;=4^N13.5
 ;;^UTILITY(U,$J,358.3,37356,2)
 ;;=^5015580
 ;;^UTILITY(U,$J,358.3,37357,0)
 ;;=N13.6^^140^1787^211
 ;;^UTILITY(U,$J,358.3,37357,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37357,1,3,0)
 ;;=3^Pyonephrosis
 ;;^UTILITY(U,$J,358.3,37357,1,4,0)
 ;;=4^N13.6
 ;;^UTILITY(U,$J,358.3,37357,2)
 ;;=^101552
 ;;^UTILITY(U,$J,358.3,37358,0)
 ;;=M06.9^^140^1787^215
 ;;^UTILITY(U,$J,358.3,37358,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37358,1,3,0)
 ;;=3^Rheumatoid arthritis, unspec
 ;;^UTILITY(U,$J,358.3,37358,1,4,0)
 ;;=4^M06.9
 ;;^UTILITY(U,$J,358.3,37358,2)
 ;;=^5010145
 ;;^UTILITY(U,$J,358.3,37359,0)
 ;;=M35.01^^140^1787^226
 ;;^UTILITY(U,$J,358.3,37359,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37359,1,3,0)
 ;;=3^Sicca syndrome w/ keratoconjunctivitis
 ;;^UTILITY(U,$J,358.3,37359,1,4,0)
 ;;=4^M35.01
 ;;^UTILITY(U,$J,358.3,37359,2)
 ;;=^5011787
 ;;^UTILITY(U,$J,358.3,37360,0)
 ;;=M35.00^^140^1787^227
 ;;^UTILITY(U,$J,358.3,37360,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37360,1,3,0)
 ;;=3^Sicca syndrome, unspec
 ;;^UTILITY(U,$J,358.3,37360,1,4,0)
 ;;=4^M35.00
 ;;^UTILITY(U,$J,358.3,37360,2)
 ;;=^5011786
 ;;^UTILITY(U,$J,358.3,37361,0)
 ;;=M35.9^^140^1787^281
 ;;^UTILITY(U,$J,358.3,37361,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37361,1,3,0)
 ;;=3^Systemic invlmnt of conn tiss, unspec
 ;;^UTILITY(U,$J,358.3,37361,1,4,0)
 ;;=4^M35.9
 ;;^UTILITY(U,$J,358.3,37361,2)
 ;;=^5011797
 ;;^UTILITY(U,$J,358.3,37362,0)
 ;;=M32.10^^140^1787^283
 ;;^UTILITY(U,$J,358.3,37362,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37362,1,3,0)
 ;;=3^Systemic lupus erythem, organ/syst involv, unspec
 ;;^UTILITY(U,$J,358.3,37362,1,4,0)
 ;;=4^M32.10
 ;;^UTILITY(U,$J,358.3,37362,2)
 ;;=^5011753
 ;;^UTILITY(U,$J,358.3,37363,0)
 ;;=M34.9^^140^1787^284
